Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6574961 | 1.00 | RIPK1 (0.53) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL30716448 | 1.00 | RIPK1 (0.53) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL29926486 | 0.88 | RIPK1 (0.55) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL525669 | 0.88 | RIPK1 (0.55) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL1200943 | 0.88 | RIPK1 (0.55) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL1142222 | 0.88 | RIPK1 (0.55) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL29860819 | 0.85 | RIPK1 (0.61) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL8710104 | 0.85 | RIPK1 (0.61) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL11828179 | 0.85 | RIPK1 (0.61) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL4837244 | 0.85 | RIPK1 (0.61) | RIPK1LMNAKDM4EL3MBTL1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815852-B2 | Carbamoyloxy arylalkan arylpiperazine analgesics | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-08-26 | — | — | US | disclosed |
| CN-101679400-B | Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound | SK HOLDINGS CO LTD | 2013-04-17 | — | — | CN | disclosed |
| EP-2150550-B1 | NOVEL CARBAMOYLOXY ARYL ALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-02-27 | — | — | EP | disclosed |
| US-20120095007-A2 | CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE ANALGESICS | SK HOLDINGS CO. LTD. (KR) | 2012-04-19 | — | — | US | disclosed |
| CN-101679400-A | Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound | SK HOLDINGS CO LTD | 2010-03-24 | — | — | CN | disclosed |
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2005-12-29 | — | — | US | disclosed |
| US-6743939-B2 | NITRIC OXIDE SYNTHASE INHIBITORS; SUCH AS 4-CHLORO-2-(((1)-4-(METHYLAMINO)-1-PHENYLBUTYL)OXY)BENZONITRILE | ASTRAZENECA AB (SE) | 2004-06-01 | — | — | US | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030105161-A1 | Novel phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6005116-A | HAVE INHIBITION ACTIVITIES AGAINST TYPE A-MONOAMINE OXIDASE; TREATING OR PREVENTING DEPRESSION, PARKINSON'S DISEASE, ALZEHEIMER'S DEMENTIA, OR CEREBROVASCULAR DEMENTIA | SANKYO COMPANY, LIMITED (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0885891-A1 | ISOXAZOLE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0226641-B1 | OXODIAZINE COMPOUNDS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-10-18 | — | — | EP | disclosed |
| US-4713381-A | ANTICOAGULANTS, ANALGESICS, ANTIINFLAMMATORY AGENT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1987-12-15 | — | — | US | disclosed |
| EP-0226641-A1 | OXODIAZINE COMPOUNDS. | YOSHITOMI PHARMACEUTICAL (JP) | 1987-07-01 | — | — | EP | disclosed |
| WO-1986007059-A2 | OXODIAZINE COMPOUNDS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1986-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | RIPK1 4526/4885LMNA 3499/4885KDM4E 2238/4885 |
| US-20120095007-A2 | CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE ANALGESICS | OPRL1, OPRD1, TRPV1 | RIPK1 4398/4885LMNA 4404/4885KDM4E 1791/4885 |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | RIPK1 731/4885LMNA 1516/4885KDM4E 4720/4885 |
| US-20030105161-A1 | Novel phenylheteroalkylamine derivatives | NOS1, CYP1A1, NOS2 | RIPK1 3036/4885LMNA 3430/4885KDM4E 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.